The design and synthesis of novel EGFR inhibitors

Simple item page
dc.contributor.authorCarnie, Robyn Elizabeth
dc.date.accessioned2020-09-07T14:32:20Z
dc.date.available2020-09-07T14:32:20Z
dc.date.issued2019
dc.descriptionA dissertation submitted in fulfillment of the requirements for the degree of Master of Science to the Faculty of Science, University of the Witwatersrand, Johannesburg, 2019en_ZA
dc.description.librarianTL (2020)en_ZA
dc.description.sponsorshipLung cancer is the second most common form of cancer, accounting for approximately 13% of all new cancer cases.Of these cancers about 85% are non-small cell lung car cinoma (NSCLC). The epidermal growth factor (EGF) receptor is a protein kinase, which is crucial in a cell’s life cycle, from cell growth to cell death. The over expres sion of the EGF receptor is observed in many forms of cancers including NSCLC, breast, ovarian, colorecteral and brain cancers. Although there are current kinase inhibitors on the market, they su↵er from dose limiting toxicity or drug resistance due to mutations in the kinase domain of EGFR. The focus of this body of work is on the development of more ecacious EGFR inhibitors that can overcome drug resistance issues associated with current EGFR inhibitors, as well as being less toxic to the body. This class of inhibitor should be a covalent inhibitor, requiring it to react with the solvent exposed cysteine residue that is positioned on the edge of the ATP binding pocket of EGFR. The carbonyl group of the ketoamide should undergo a 1,2 addition with this cysteine residue to form a covalent, yet reversible bond. We report herein our progress towards the synthesis and biological evaluation of a novel class of quinazoline ketoamides. The key step in this synthesis route was to form a thiol on the quinazoline core. This was to be achieved by the addition of a thiocabamoyl group to the exposed alcohol 33 to form O-4-[(3-bromophenyl)amino] 7-methoxyquinazolin-6-yldimethylcarbamothioate 49, this compound successfully un derwent the Miyazaki-Newman-Kwart rearrangement, in which the oxygen and sulfur are exchanged to form S-4-[(3-bromophenyl)amino]-7-methoxyquinazolin-6-yldimethyl carbamothioate 48 , allowing the sulfur to be on the quinazoline core. the characterisation for this compound included 1H NMR spectroscopy and 13C NMR spec troscopy to confirm it’s structure. The same rearrangement was attempted on the 3 chloro-4-fluoro analogue O-4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin 6-yldimethylcarbamothioate 66, however this rearrangement was not successfully iso lated and characterised. The next step required the carbamoyl group to be removed to expose the thiol. Although this step was attempted on both analogues, the products 4-[(3-bromo)amino]-7-methoxyquinazolin-6-thiol 47 and 4-[(3-chloro-4-fluoro)amino] 7-methoxyquinazolin-6-thiol 67 were not successfully synthesised and isolated.en_ZA
dc.facultyFaculty of Scienceen_ZA
dc.format.extentOnline resource (102 leaves)
dc.identifier.citationCarnie, Robyn Elizabeth (2019) The design and synthesis of novel EGFR inhibitors, University of the Witwatersrand, Johannesburg, <http://hdl.handle.net/10539/29538>
dc.identifier.urihttps://hdl.handle.net/10539/29538
dc.language.isoenen_ZA
dc.subject.lcshCancer--Chemotherapy
dc.subject.lcshDrug targeting
dc.titleThe design and synthesis of novel EGFR inhibitorsen_ZA
dc.typeThesisen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Robyn_Carnie 13March2019_Signed.pdf
Size:
3.04 MB
Format:
Adobe Portable Document Format
Description:
Main Work
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ETD Collection